Role of neoadjuvant therapy for nonmetastatic pancreatic cancer: Current evidence and future perspectives

Table 1 Trials investigating the role of neoadjuvant chemotherapy for resectable pancreatic adenocarcinoma

Ref.	Study type	Treatment	No. of patients	Resection rate (%)	Median OS (mo)
Talamonti et al[23], 2006	Single arm, phase II	Gem + RT	22	85	261
Evans et al[113], 2008	Single arm, phase II	Gem + RT	86	74	22
Heinrich et al[24], 2008	Single arm, phase II	Gem or Cis	28	89	27
Varadhachary et al[114], 2008	Single arm, phase II	Gem/Cis	90	58	19
O’Reilly et al[115], 2014	Single arm, phase II	GemOx	38	71	27
Golcher et al[116], 2015	Randomized, double arm, phase II	Gem/Cis + RT vs upfront surgery	66	19 vs 23	17.4 vs 14.4 (P = 0.96)
Okano et al[117], 2017	Single arm, phase II	S1 + RT	33	962	NA
Motoi et al[118], 2019	Randomized, double arm, phase II/III	GemS1 vs upfront surgery	364	NA	37
Versteijne et al[25], 2022	Randomized, double arm, phase III	Gem + RT vs upfront surgery	246	NA	15.7 vs 14.32

¹Calculated only in resected patients.

²Cumulative results for both resectable- and borderline resectable- pancreatic adenocarcinoma.

Gem: Gemcitabine; Ox: Oxaliplatin; Cis: Cisplatin; RT: Radiotherapy; OS: Overall survival; NA: Not available.